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Abstract
Background: Hypermethylation of promoter CpG islands is strongly correlated to transcriptional
gene silencing and epigenetic maintenance of the silenced state. As well as its role in tumor
development, CpG island methylation contributes to the acquisition of resistance to
chemotherapy. Differential Methylation Hybridisation (DMH) is one technique used for genome-
wide DNA methylation analysis. The study of such microarray data sets should ideally account for
the specific biological features of DNA methylation and the non-symmetrical distribution of the
ratios of unmethylated and methylated sequences hybridised on the array. We have therefore
developed a novel algorithm tailored to this type of data, Methylation Linear Discriminant Analysis
(MLDA).
Results: MLDA was programmed in R (version 2.7.0) and the package is available at CRAN [1].
This approach utilizes linear regression models of non-normalised hybridisation data to define
methylation status. Log-transformed signal intensities of unmethylated controls on the microarray
are used as a reference. The signal intensities of DNA samples digested with methylation sensitive
restriction enzymes and mock digested are then transformed to the likelihood of a locus being
methylated using this reference. We tested the ability of MLDA to identify loci differentially
methylated as analysed by DMH between cisplatin sensitive and resistant ovarian cancer cell lines.
MLDA identified 115 differentially methylated loci and 23 out of 26 of these loci have been
independently validated by Methylation Specific PCR and/or bisulphite pyrosequencing.
Conclusion: MLDA has advantages for analyzing methylation data from CpG island microarrays,
since there is a clear rational for the definition of methylation status, it uses DMH data without
between-group normalisation and is less influenced by cross-hybridisation of loci. The MLDA
algorithm successfully identified differentially methylated loci between two classes of samples
analysed by DMH using CpG island microarrays.
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Background
DNA methylation frequently occurs in mammalian DNA
at the 5 position of cytosine in CpG dinucleotides. It has
been estimated that over 70% of cytosines of CpG dinu-
cleotides are methylated in the human genome. CpG
dinucleotides are under-represented in the genome and
methylated CpG dinucleotides predominantly occur
within repetitive elements [2]. However, there are CpG
rich regions of the genome which generally remain
unmethylated [3]. These CpG rich regions are known as
CpG islands and are frequently located in the promoter or
the first exon regions of approximately 60% of all genes
[4]. The unmethylated status of CpG islands is thought to
be a prerequisite state to maintain the linked gene in an
active transcribed and transcriptional permissive state.
Differential Methylation Hybridisation (DMH) is one of
several techniques for examining CpG island methylation
at a genome-wide scale that has been applied to the iden-
tification of aberrantly methylated gene promoters in var-
ious cancers [5-12]. Nouzova et al[13] modified the
original method by using digestion with a methylation-
dependent enzyme, McrBC. This enzyme only cleaves
methylated CpG DNA sequences. Within-sample compar-
ison is applied after competitive hybridisation with
McrBC digested DNA and undigested (mock digested)
DNA labelled with Cy3 and Cy5. If a locus is unmethyl-
ated the signal intensities of Cy3 and Cy5 are equivalent,
while if methylated the Cy5/Cy3 (undigested/digested)
ratio is greater than one. However, no common reference
is generally used in the modified DMH method, and the
unequal representation of methylated and unmethylated
sequences due to competitive hybridisation may reduce
sensitivity and specificity to detect differential methyla-
tion.
Currently, Significance Analysis of Microarrays (SAM)
[14] and Prediction Analysis for Microarrays (PAM) [15]
are commonly applied in DNA methylation analysis.
Based on the change in hybridisation relative to the stand-
ard deviation of repeated measurements, SAM assigns
each gene a score that is an extension of the t-statistic. For
significant genes with a score over a certain threshold,
SAM uses permutations to estimate the false discovery rate
(FDR). It has been implemented in many studies of gene
expression data [16-21] as well as DMH data, e.g. Wei et
al. [22] applied SAM to find the differential methylation
of CpG island loci between ovarian caner patient groups
with short and long progression-free survival (PFS). How-
ever, SAM assumes that the microarray data conform to
approximate normality and symmetry, leading to the loss
of power in the analysis of DMH data that are inherently
skewed due to the biological features of DNA methylation
in cancer and competitive hybridisation on DMH arrays
(Figure 1).
In the modified DMH method, the ratios of raw signal
intensities (undigested/digested) greater than 1 reflect the
various methylation levels [13]. A ratio cut-off is generally
used to identify the hypermethylated loci [7]. However,
this is an arbitrary value and does not necessarily accu-
rately reflect the various sources of variation in the exper-
iment. It is therefore desirable to develop an algorithm to
more objectively assess the methylation status of loci from
DMH data.
PAM is a nearest centroid shrinkage method that identifies
those genes that discriminate best between classes. This
technique shrinks the class gene centroid towards the
overall centroid by a "threshold" amount after standardiz-
ing each gene by its within class standard deviation. The
"threshold" is identified by cross-validation. This
approach was applied in the study by Wei et al. [22] and
showed certain power in the identification of differen-
tially methylated loci, but PAM is designed for class pre-
diction rather than class comparison. Although the class
predictor used in PAM can reflect the difference between
classes, a large number of loci actually differentially meth-
ylated between the classes are excluded to improve the
accuracy of prediction.
Although normalisation has become a standard proce-
dure for the study of microarray data and is necessary for
SAM and PAM analysis, unbalanced shifts in methylation
status between class samples in DMH limit the use of
between-class normalisation which assumes the changes
are roughly symmetric. Thus, the differential methylation
can be masked by the over-correction of normalisation
Distribution of log-transformed ratio of gene expression data  in breast cancer and DMH data in A2780 cell line Figure 1
Distribution of log-transformed ratio of gene expres-
sion data in breast cancer and DMH data in A2780 
cell line. The left histogram shows the distribution of log-
transformed ratios (cy3/cy5) in gene expression profiling data 
from a previous study of breast cancer 36] which is symmet-
ric, while the right histogram shows the log-transformed 
ratios (undigested/digested) of DMH data from the present 
study which is skewed.BMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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and it would be preferable to use a method of analysis that
does not require normalisation of the data.
Since PAM and SAM may have limitations for analysing
DMH data, we have developed an alternative approach
based on the specific features and known biological prop-
erties of the arrays used for DMH analysis. The algorithm
is named as Methylation Linear Discriminant Analysis
(MLDA) and has been applied to identify a set of loci dif-
ferentially methylated between ovarian cisplatin sensitive
and resistant cancer cell lines.
Results
Outline of MLDA
In this study, we have developed a novel approach, named
MLDA, for analysing CpG island microarray hybridisation
data that allows the identification of differentially methyl-
ated loci. MLDA was programmed in R (version 2.7.0)
and the package is available at CRAN [1]. This approach
uses three relatively simple linear regression models. The
first one is constructed by the log-transformed signal
intensities of unmethylated features and used as the refer-
ence for unmethylation (Figure 2b). The second one is the
intermediate model constructed through the point corre-
sponding to the 97.5-quantiles residual below the first lin-
ear regression line (Figure 2c). The features with a
standardised residual less than 2 from this intermediate
model are used to generate the third model which is used
as the reference for methylation (Figure 2d). The log like-
lihood ratio of a locus being methylated is then propor-
tional to the difference between the squared standardised
residual from the methylated line and that from the
unmethylated line. The log likelihood threshold of zero
then provides a more rational basis for distinguishing
between methylated and unmethylated loci than a robust
undigested/digested ratio of 1.5, as it takes into account
the observed variability in the experiment.
In our approach the consistency and inconsistency rates of
log likelihood ratios on dye-swapped/duplicate arrays are
used to determine methylation and unmethylation cut-
offs, which keep the consistency rate (CR) relatively high
(about 140%) and the inconsistency rate (IR) low (about
1%). Each loci is assigned a score based on the cut-offs
using the weighted methylation scoring scheme. The fea-
ture consistently identified as methylated candidates on
dye-swapped/duplicate arrays are scored as 1; similarly
unmethylated features are scored as -1; the rest of the fea-
ture are assigned a weighted score corresponding to their
location on the plot of log-likelihood ratios (Figure 3).
The averaged score for each locus is calculated in each
sample class (e.g. resistant or sensitive) and plotted
against each other. A robust regression model is then fit-
ted to these data. The standardised residuals from the
robust regression model are assumed to follow a normal
distribution  N(μ,  σ2). The outliers of the standardised
residuals are identified as the differentially methylated
loci between the class samples.
DMH dataset
MLDA was applied to identify the CGIs differentially
methylated from DMH data derived from sensitive A2780
derivatives (A2780, A2780p3, A2780p5, A2780p6,
A2780p13, A2780p14) and isogenically matched, resist-
ant lines [23] derived by multiple exposures to cytotoxic
levels of cisplatin and which are 2–5 fold resistant to cis-
platin in clonogenic assays (A2780cp70, A2780/MCP1,
A2780/MCP2, A2780/MCP3, A2780/MCP4, A2780/
MCP5, A2780/MCP6, A2780/MCP7, A2780/MCP8,
A2780/MCP9). After background correction, the log-
transformed digested and undigested intensities of the
13056 microarray probes show three approximately par-
allel linear patterns (Figure 2a). The first pattern
(digested/undigested is close to 1) represents the unmeth-
ylated sequences. The second pattern represents either
hemi-methylated sequences or the unmethylated
sequences cross-hybridised with the methylated ones on
the panel. The third pattern represents the methylated
sequences in target DNA. The methylated and unmethyl-
ated loci in target DNA can be characterised by a linear
regression model for each pattern. As previously men-
tioned, normalisation may not be appropriate for DMH
data, so the log ratios of signal intensities in two classes of
samples are not at the same level (Figure 4). Normalisa-
tion is not required for MLDA as the determination of the
methylation score is based on the data within each exper-
iment.
Mitochondrial DNA is unmethylated [24], therefore, the
signal intensities of both channels of microarray probes
for mitochondrial sequences are expected to be equal.
However, a bi-modal distribution is observed in the log-
transformed fluorescence ratios (digested/undigested) of
121 mitochondrial sequences. The first peak represents
the unmethylated mitochondrial sequences and the sec-
ond lower peak is assumed to be the mitochondrial
sequences cross-hybridised with other methylated
sequences on the panel. Thus, we selected 94 of 121 mito-
chondrial sequences that were consistently unmethylated
through all the cell lines and used them as the unmethyl-
ation reference in target DNA.
The parameters of those two models in all 16 cell lines
were estimated (Table 1). The slope of the unmethylated
regression line constructed by 94 mitochondrial
sequences is indeed close to 1. After computing the log-
likelihood ratios, the methylation and unmethylation cut-
offs and associated IRs and CRs were determined from the
dye-swapped array pairs (details in Method section). AsBMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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shown in Figure 5, IR tends to rise with the increase of CR
slowly, but starts to increase dramatically when the CR
goes above 140%, at which point IR is generally about
1%. We have therefore used CR > 140% and IR < 1% as
the criteria for determining the methylation and unmeth-
ylation cut-offs. Each locus was scored using the weighted
scoring scheme based on those cut-offs. The averaged
scores in 6 cisplatin-sensitive cell lines and 10 cisplatin-
resistant cell lines were used to construct a robust regres-
sion model. Figure 6a shows that the standardised residu-
An illustration of unmethylated and methylated model construction in MLDA in A2780 cell line Figure 2
An illustration of unmethylated and methylated model construction in MLDA in A2780 cell line. a: Three pat-
terns can be observed on the scatter plot of log-transformed Cy3 (undigested) against log-transformed Cy5 (digested) intensi-
ties. b: The unmethylated model constructed using 94 mitochondrial sequences as a unmethylation reference. c: The 
intermediate model constructed through the 97.5 quantile residual. The point X is the 97.5 quantile residual. The microarray 
probes colored in blue (standardised residual to the intermediate model is less than 2) are selected to construct the methyl-
ated model. d: Methylated (in blue) and unmethylated (in red) models in A2780 cell line.
a b
d c
X(R.975,G.975)BMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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als (residual/σ) from the robust regression model roughly
follow a normal distribution. The positive and negative
outliers are determined as described in Method section.
Finally, 115 loci were identified as candidates differen-
tially methylated between A2780 sensitive and these
resistant cell lines (additional file 1). Noticeably, 113 of
115 loci (p = 8.8 × 10-3, outlier detection test [25]) were
hypermethylated, but only 2 loci (p < 0.001, outlier detec-
tion test) lost methylation in the resistant cell lines (Figure
6b). This is consistent with the unbalanced shift in DMH
data and indicates cisplatin treatment of cells selects pref-
erentially for hypermethylation of loci, rather than
hypomethylation in these tumor cells.
Validation of differential methylation
To confirm the differential methylation of loci identified
in this study, we experimentally tested the methylation of
26 loci by methylation-specific PCR (MSP) and/or pyrose-
quencing of bisulphite modified DNA [26] in sensitive
A2780 derivatives and cisplatin resistant derivatives.
Twenty-three out of the 26 loci have been confirmed as
differentially methylated (additional file 1). It should be
noted that MSP and pyrosequencing only examine meth-
ylation at a limited number of CpG sites of the sequence
present on the DMH analysis. It is possible that the loci
which were not confirmed as differentially methylated are
methylated at other CpG sites which are detected by DMH
but not targeted by MSP and/or pyrosequencing primers
and so 23 out of 26 loci confirmed as differentially meth-
ylated is a minimum estimation.
To compare the results from MLDA, SAM and PAM, we
analysed the DMH dataset by all three methods. MLDA
identified 115 loci (113 hypermethylated and 2
hypomethylated loci, misclassification error < 0.001),
SAM identified 152 loci (149 hypermethylated and 3
hypomethylated loci, misclassification error = 0.227, FDR
= 6.17 × 10-3), and PAM found 24 hypermethylated loci
(misclassification error = 0.084, FDR < 0.001) in the
resistant cell lines. Twenty-four loci identified by all three
methods are listed in Table 2.
Discussion
Hypermethylation of promoter CpG islands is strongly
correlated to transcriptional gene silencing and epigenetic
maintenance of the silenced state and is a potential rich
source of biomarkers of cancer. Differential Methylation
Hybridisation (DMH) is one technique used for genome-
wide DNA methylation analysis. The study of such micro-
array data sets should ideally account for the specific bio-
logical features of DNA methylation and the non-
symmetrical distribution of the ratios of unmethylated
and methylated sequences hybridised on the array. We
Weighted scoring scheme Figure 3
Weighted scoring scheme. The microarray probes con-
sistently identified as methylated candidates on dye-swap 
arrays were scored 1; similarly unmethylated microarray 
probes were scored -1. The rest of the microarray probes 
were assigned a weighted score based on their location on 
the plot. LRmeth: log likelihood ratio cut-off for methylated 
loci; LRunmeth: log likelihood ratio cut-off for unmethylated 
loci. LR: log likelihood ratio on dye-swapped arrays.
Box plot of log ratios of undigested signal intensities against  digested signal intensities in 16 cell lines (dye-swapped  arrays) Figure 4
Box plot of log ratios of undigested signal intensities 
against digested signal intensities in 16 cell lines (dye-
swapped arrays). The boxes colored in red are the A2780 
sensitive cell lines; in blue are the A2780 resistant cell lines. 
As normalisation is not applied, the center and scale of log 
ratios for the 16 cell lines are not at the same level.BMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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have therefore developed a novel algorithm tailored to
this type of data, Methylation Linear Discriminant Analy-
sis (MLDA). MLDA utilises log likelihood ratios represent-
ing the relative probability that loci are methylated
instead of log ratios of signal intensities used in previous
studies [6-10,27]. Validation of 23/26 identified loci
using independent methods of methylation analysis
shows that MLDA can robustly identify differential meth-
ylated loci between ovarian cancer sensitive and resistant
cell lines without requiring the data to be normalised.
Although a log likelihood ratio above zero means that the
locus tends to be methylated, we did not use zero as the
cut-off to determine the number of methylated and
CR against IR in 16 cell lines Figure 5
CR against IR in 16 cell lines. X axis is the consistency rate (CR) and y axis is the inconsistency rate (IR). IR tends to rise 
with the increase of CR slowly, but starts to increase dramatically when the CR goes above 140%, at which point the inconsist-
ency rate is generally about 1%. Not all cell lines could reach this point e.g. MCP3.BMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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unmethylated sequences, as the existence of cross-hybrid-
isation and measurement errors in the DMH assay makes
this unreliable. To increase the precision of the methyla-
tion classification, we used the inconsistency (IR) and
consistency (CR) rates between the dye-swap arrays to
determine likelihood ratio cut-offs for methylation and
unmethylation and assigned each locus a methylation
score based on the position relative to these cut-offs. As
shown in Figure 5, not all cell lines can reach the point
that CR is around 140% and IR is about 1%. IR and CR
need to be carefully selected as the methylation scores of
loci are consequently influenced by the change of IR and
CR. We also observed a lower CR (about 120%) and a
higher IR (about 2%) in another CpG island array using
DMH (data not shown), therefore, further examination of
what factors influence the achievable CR and IR rates may
improve the utility of the MLDA approach.
Data on methylation status for 121 mitochondrial derived
sequences were available in this study. Mitochondrial
sequences would be expected to be unmethylated. We
used 94 mitochondrial sequences to construct unmethyl-
ated linear model at the beginning of the study, and
indeed, 93 of 121 mitochondrial loci were defined as
unmethylated and 25 loci being of uncertain methylation
status by MLDA. However, three mitochondrial loci were
identified as hypermethylated candidates in the resistant
ovarian carcinoma cell lines by both MLDA and SAM.
One explanation of this discrepancy is that all these three
loci have more than one BLAT hit indicating the existence
of homology with nuclear DNA sequences, raising the
possibility of hybridisation with these nuclear DNA
sequences which may be differentially methylated. As
shown in Figure 2a, the loci in the middle pattern repre-
sent either hemi-methylated sequences or the unmethyl-
ated sequences cross-hybridised with the methylated ones
on the panel. No specific allowance is made for these
intermediate points in analysis by SAM and PAM, whereas
MLDA attempts specifically to down-weight these points
in the identification of the methylation regression line. By
giving a lower weighted score (close to 0) (Figure 3) to
those loci, MLDA reduces the influence of cross-hybridisa-
tion among this group of sequences. Of course cross-
hybridisation may also occur in the loci in the other two
patterns (methylated and unmethylated patterns), but it is
not possible for any mathematical approach to identify
this.
The misclassification error of MLDA based on the methyl-
ation score is much lower than that for either SAM or PAM
based on the log ratios, indicating the potential of MLDA
methylation scores to be used as a reliable discriminator
between classes of samples.
Conclusion
We have developed a novel method, named MLDA, for
genome-wide DNA methylation studies. MLDA can trans-
form the signal intensities to log-likelihood ratios through
three linear regression models. Using this approach
MLDA allows determination of the methylation status of
a locus based on dye-swapped/duplicate arrays. The
method has been applied to assess the methylation status
of each locus and identified 115 loci that exhibit differen-
tial methylation between A2780 sensitive and resistant
cell lines. A minimum of 23 out of 26 loci have been con-
firmed by independent methods as differentially methyl-
ated.
Methods
First, all intensity values were log transformed. A multipli-
cative background correction was applied to correct signal
intensities for the background noise in each array. After
background correction, the log-transformed digested and
undigested intensities show three approximately parallel
linear patterns (Figure 2a). The first pattern (digested/
undigested is close to 1) represents the unmethylated
sequences. The second pattern represents either hemi-
methylated sequences or the unmethylated sequences
cross-hybridised with the methylated ones on the panel.
The third pattern represents the methylated sequences in
target DNA. The methylated and unmethylated loci in tar-
get DNA can be characterised by a linear regression model
for each pattern. The distance of each spot to the methyl-
ated and unmethylated lines respectively can then be esti-
mated by standardised residuals. The log likelihood ratio
of a locus being methylated is then proportional to the
difference between the squared standardised residual
from the methylated line and that from the unmethylated
Outliers identifications Figure 6
Outliers identifications. a: Distribution of the observed 
(histogram) standardised residuals and the theoretical distri-
bution based on the fitted model (dashed smooth line in red). 
The red and blue solid line are the positive and negative cut-
offs, respectively. b: Scatter plot of sensitive scores against 
resistant scores in A2780 series cell lines. The hypermethyl-
ated loci are colored in red and hypomethylated loci are in 
blue. The robust regression model is Y = 0.9956X + 0.0019.
a bBMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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one. The algorithm based around this regression approach
is named Methylation Linear Discriminant Analysis
(MLDA) and was programmed in R version 2.7.0.
Log-likelihood ratio transformation
a An univariate linear regression model was constructed
for the unmethylated probes (e.g. mitochondrial derived
features) using formula (1) where α is the intercept, β is
the slope of the model, and ξ is the error representing the
unpredicted or unexplained variation in the model (Fig-
ure 2b). The parameters of regression line were estimated
by the method of least squares (formula 2 and 3).
Gi = α + βRi + ξi i = 1,2,3.......k (1)
k is the number of unmethylated controls on DMH array.
Gi and Ri are the logarithmic-transformed digested and
undigested intensities of microarray probes for mitochon-
drial sequences, respectively.   and   are the averaged
logarithmic-transformed undigested and digested intensi-
ties of the k unmethylated controls.
ˆ () ()
()
, , ....... b =
−− ∑
− ∑
=
Ri RG i G
Ri R
ik 2 123 (2)
ˆ ˆ ab =− RG (3)
G R
Table 1: Parameters of linear models in MLDA for 16 cell lines in DMH dataset I
Unmethylation linear regression model
cell line intercetp (α)s l o p e  ( β) σ R2 interceptds (α)s l o p e ds (β) σds R2ds
A2780 -0.0003 1.0122 0.1727 0.9829 0.0005 1.0574 0.1897 0.978
A2780p3 -0.0003 1.0343 0.1212 0.9897 0.0018 1.1065 0.1425 0.9882
A2780p5 -0.0003 1.0138 0.1684 0.984 -0.0002 1.0728 0.1425 0.9883
A2780p6 0.0002 0.9914 0.1605 0.9778 -0.0001 1.0012 0.1638 0.9747
A2780p13 -0.0012 1.024 0.1628 0.9786 -0.0005 1.0744 0.1436 0.9852
A2780p14 -0.0022 1.0499 0.1523 0.9809 -0.0009 1.034 0.2069 0.9691
A2780cp70 0.0013 0.9604 0.2532 0.9524 -0.0002 1.0119 0.2402 0.9479
MCP1 0.0002 0.9946 0.145 0.9803 -0.0023 1.112 0.1452 0.9836
MCP2 0.0000 0.998 0.137 0.9727 -0.0028 1.0475 0.1719 0.9653
MCP3 0.0004 0.9932 0.2253 0.9183 -0.0023 1.0517 0.2795 0.8978
MCP4 0.0006 0.9838 0.1739 0.9718 -0.0028 1.077 0.1947 0.9751
MCP5 0.0009 0.9857 0.2464 0.9639 -0.0008 1.017 0.2166 0.9692
MCP6 -0.0022 1.0352 0.122 0.9751 -0.0068 1.1283 0.154 0.9752
MCP7 -0.0005 1.0079 0.1379 0.9791 -0.0045 1.1529 0.1588 0.9764
MCP8 -0.0028 1.0578 0.1903 0.9431 -0.0068 1.1193 0.1885 0.9575
MCP9 -0.0017 1.0331 0.1834 0.9614 -0.0091 1.1538 0.1691 0.9674
Methylation linear regression model
cell line intercetp (α)s l o p e  ( β) σ R2 interceptds (α)s l o p e ds (β) σds R2ds
A2780 -0.8839 0.8917 0.1491 0.9438 -0.8055 0.9086 0.1706 0.926
A2780p3 -1.1672 0.9797 0.1518 0.9553 -0.7414 0.9774 0.179 0.9438
A2780p5 -0.8991 0.8978 0.1515 0.9476 -0.9246 0.9766 0.1673 0.9523
A2780p6 -0.9455 0.9562 0.1838 0.9378 -1.1995 0.9641 0.1788 0.9324
A2780p13 -1.8918 0.9807 0.2535 0.8962 -1.8049 0.9652 0.2936 0.8512
A2780p14 -1.5637 0.9142 0.2549 0.8857 -1.4468 0.9066 0.2128 0.8837
A2780cp70 -1.0317 0.8501 0.1581 0.9115 -1.3074 0.8967 0.1541 0.9265
MCP1 -1.199 0.9781 0.1692 0.9467 -1.0935 1.0384 0.1775 0.9525
MCP2 -0.8037 0.9292 0.1486 0.9557 -0.9738 0.9381 0.2176 0.8848
MCP3 -1.1244 0.9151 0.1755 0.9482 -0.9303 0.9205 0.2599 0.8098
MCP4 -1.4326 0.9171 0.1418 0.966 -1.6205 0.961 0.2348 0.8323
MCP5 -1.1187 0.9425 0.1839 0.9404 -1.2007 0.9546 0.1757 0.9295
MCP6 -1.246 0.925 0.1966 0.9294 -1.2182 0.9826 0.2248 0.8989
MCP7 -1.8972 0.9909 0.1977 0.9442 -1.4894 1.0139 0.2458 0.8886
MCP8 -1.0219 0.9905 0.1975 0.9468 -0.4735 0.9421 0.228 0.8761
MCP9 -1.3399 0.9837 0.2073 0.9352 -1.1497 1.0078 0.1967 0.9115
ds: dye swap
σ: standard deviation
R2: coefficient of determinationBMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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b. The scale estimate σmito associated with the error term
in the linear regression model was estimated from the
residuals from the observed k points to the fitted line. The
most extreme 10% of residuals was omitted from either
end of the distribution to minimise the impact of extreme
residuals on this estimate.
c. The standardised residuals of all the microarray probes
to the unmethylation regression line were calculated as
formula (4).
d. The point corresponding to the 97.5-quantiles residual
below the unmethylation line is represented as X (R.975,
G.975). The intermediate linear model (Figure 2c) was
constructed through point X with a slope assumed to be 1
and the intercept estimated as formula (5).
e. The standardised residuals of all the microarray probes
to the line with slope 1 and intercept estimated from (5)
were calculated as formula (6). The variance of the resid-
uals to the intermediate model was assumed to be similar
as that in the mitochondrial model.
f. The microarray probes with standardised residuals less
than 2 were included for later robust regression analysis.
The line estimated from this regression analysis represents
the methylation regression line (Figure 2d).
g. The scale estimate σmeth of the methylation regression
line was estimated using only those microarray probes
below the line, with the most extreme 5% removed.
h. The standardised residuals of all the microarray probes
to the methylated regression line were calculated as for-
mula (7). The log likelihood ratio (LR) of all the microar-
ray probes was estimated by formula (8) for further
analysis.
SR
residualsmito
mito
mito =
s
(4)
ˆ . .. as =−+ GR mito 975 975 19 6 (5)
SR
residuals
mito
.
.
975
975 =
s
(6)
Table 2: 24 loci identified by MLDA, PAM and SAM as differentially methylated candidates in the comparison between A2780 cisplatin 
sensitive and cisplatin multiple-selected resistant cell lines.
microarray 
ID
status validation MLDA 
rank*
PAM 
rank
SAM 
rank
CGI*** gene 
symbol**
GenBank 
Accession
Chromoso
me
66_G_6 hypermethylated Yes 1 1 1 Yes
121_D_9 hypermethylated Yes 2 5 6 Yes CRABP1 NM_004378 15
39_E_1 hypermethylated ND 3 2 2 No
122_D_9 hypermethylated No 4 11 11 Yes SOX12 NM_006943 20
123_D_9 hypermethylated No 5 10 10 Yes SOX12 NM_006943 20
51_H_8 hypermethylated Yes 6 18 19 No FEZF2 NM_018008 3
58_A_1 hypermethylated ND 7 22 22 Yes
80_H_5 hypermethylated ND 8 14 16 No
21_A_11 hypermethylated Yes 9 17 18 Yes NTN4 NM_021229 12
38_D_7 hypermethylated Yes 11 23 24 Yes AGBL2 NM_024783 11
40_E_1 hypermethylated ND 12 19 17 No
18_A_7 hypermethylated ND 13 20 20 No EDIL3 NM_005711 5
55_F_8 hypermethylated Yes 14 9 9 Yes BC127881 BC127881 7
122_B_1 hypermethylated ND 15 16 14 No
109_A_6 hypermethylated No 18 12 13 Yes
41_D_9 hypermethylated Yes 22 8 8 Yes WNT1 NM_005430 12
42_D_9 hypermethylated ND 23 4 4 No
119_A_6 hypermethylated Yes 24 6 5 Yes NR2E1 NM_003269 6
63_A_8 hypermethylated ND 26 15 15 No
6_D_4 hypermethylated Yes 31 3 3 Yes LMX1A NM_177398 1
17_H_9 hypermethylated Yes 34 13 12 Yes HRASLS3 NM_006290 6
5_D_4 hypermethylated Yes 35 7 7 Yes LMX1A NM_177398 1
24_D_3 hypermethylated Yes 75 24 23 Yes SP5 NM_001003845 2
122_G_1 hypermethylated ND 101 21 21 Yes
ND: not done. Yes: validated. No: not validated
MLDA rank*: the rank of standardised residuals to the robust regression line constructed by the averaged sensitive scores against averaged 
resistant scores
Gene symbol**: only the gene of which transcription start site (TSS) is within 5 kb span of the loci
CGI***: CpG island defined by Gardiner-Garden and Frommer [31].BMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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LR = SR2
mito - SR2
meth (8)
Determination of log likelihood ratio cut-offs
Two inconsistency rates (IRmeth and IRunmeth) and two con-
sistency rates (CRmeth and CRunmeth) between dye-swap
arrays were used to determine the log like likelihood ratio
threshold. IRmeth (formula 9) represents the rate of the
microarray probes identified as methylated in one array
but as unmethylated in the other one, while IRunmeth (for-
mula 10) is the rate of the microarray probes identified as
unmethylated in one array but as methylated in the other
one. CRmeth (formula 11) and CRunmeth (formula 12) are
the rates for the spots identified as methylated (CRmeth)
and unmethylated (CRunmeth) in both dye-swap arrays
(Figure 7).
b The log likelihood ratio thresholds (LRmeth and LRun-
meth) for methylated and unmethylated microarray
probes, which kept the IR rates low (at or close to 1%) and
the CR rates high (at or close to 140%), were used as the
cut-offs for methylated and unmethylated loci. IR tends to
rise with the increase of CR slowly, but starts to increase
dramatically when the CR goes above 140%, at which
point the inconsistency rate is generally about 1%. We
have therefore used CR > 140% and IR < 1% as the criteria
for determining the methylation cut-offs.
Identification of robust regression outliers
Each microarray probe was scored based on the cut-offs of
likelihood ratios for methylation and unmethylation on
dye-swap arrays using the weighted methylation scoring
scheme shown in Figure 3. The microarray probes consist-
ently identified as methylated candidates on dye-swap
arrays were scored of 1; similarly unmethylated microar-
ray probes were scored of -1. The rest of the microarray
probes were assigned a weighted score based on their loca-
tion on the plot.
A robust regression model [28] was constructed with the
averaged scores in one class of samples as the explanatory
variable, and the corresponding scores in the other class of
samples as the dependent variable. The degree of trim-
ming was determined according to Barnett et al. [29] when
estimating the variance of residuals to the robust linear
regression model.
It was assumed that the standardised residuals (SRs) from
the robust regression line followed a normal distribution
N(μ, σ2). μ and σ were estimated excluding outliers using
the MAD-Median Rule [30]. The p value for each SR cut-
off was calculated as described by Simon et al [25]. This p-
value reflects the probability of observing a group of more
extreme residuals from the fitted normal distribution.
Microarray probes were identified as outliers if their SRs
were larger than the cut-off for which the p-value was less
than 0.01.
SR
residualsmeth
meth
meth =
s
(7)
IR
c
cfi
g
ghi
meth =
++
+
++
(9)
IR
g
adg
c
abc
unmeth =
++
+
++
(10)
CR
i
cfi
i
ghi
meth =
++
+
++
(11)
CR
a
abc
a
adg
meth =
++
+
++
(12)
Determination of methylation and unmethylation cut-offs of  likelihood ratios on dye-swapped arrays Figure 7
Determination of methylation and unmethylation 
cut-offs of likelihood ratios on dye-swapped arrays. 
LRmeth: log likelihood ratio cut-off for methylated spots; 
LRunmeth: log likelihood ratio cut-off for unmethylated 
spots.
Table 3: Classification of loci
Unmethylated uncertain methylated
Unmethylated a b c
Uncertain d e f
Methylated g h iBMC Bioinformatics 2008, 9:337 http://www.biomedcentral.com/1471-2105/9/337
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Estimation of misclassification rate
The misclassification rate was estimated by drawing boot-
strap samples 500 times with replacement from the two
classes (sensitive and resistant) and carrying out hierarchi-
cal clustering based on the loci identified as differentially
methylated using weighted scores for MLDA and log ratios
without between-group normalisation for SAM and PAM,
respectively. Clustering was carried out using Euclidean
distance as the distance metric, and clusters were agglom-
erated using the average linkage criterion. The clustering
tree was cut into two groups and the number of misclassi-
fied cell lines was counted. The misclassification rate was
obtained from the averaged number of misclassified sam-
ples in 500 bootstraps divided by the total number of
samples.
SAM and PAM analysis
The raw signal intensities of each channel were subtracted
by the median signal intensities of corresponding channel
of controls on HCGI12K array. After this correction, SAM
in samr package and PAM in pamr package were applied
using log ratios (digested/undigested) in R version 2.7.0.
Between-group normalisation was not used in SAM and
PAM to avoid over-correction masking the differential
methylation.
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